RaPID Bloodstream Infection Panel
Diagnosis of bloodstream infections/sepsis
Key Facts
About HelixBind
HelixBind is a private, pre-revenue diagnostics company tackling the critical global health challenge of sepsis and bloodstream infections. Its core innovation is an automated, cassette-based diagnostic platform that delivers species-level identification of over 20 pathogens, along with antimicrobial resistance markers, directly from a blood sample in approximately four hours—a dramatic improvement over the standard 2-3 day blood culture process. By providing rapid, actionable results, HelixBind aims to enable earlier, targeted antimicrobial therapy, thereby improving patient survival, combating antimicrobial resistance, and reducing healthcare costs associated with sepsis management. The company is in the development and commercialization preparation stage, actively hiring to grow its team.
View full company profile